NCT05274100View on ClinicalTrials.gov

Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

July 6, 2021

Study Completion Date

July 6, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

Risankizumab

Subcutaneous Injection via prefilled syringe (PFS)

DRUG

Risankizumab

Intravenous Infusion

DRUG

Risankizumab

Subcutaneous Injection via on-body delivery system (OBDS)

Trial Locations (8)

33014

Clinical Pharmacology of Miami /ID# 225392, Miami

53095

Spaulding Clinical Research LLC /ID# 225405, West Bend

60030

Acpru /Id# 222349, Grayslake

78744

PPD Clinical Research Unit - Austin /ID# 222361, Austin

90630

Altasciences Clinical Los Angeles, Inc /ID# 222238, Cypress

92801-2658

Anaheim Clinical Trials LLC /ID# 222821, Anaheim

32806-1044

PPD Clinical Research Unit /ID# 222362, Orlando

89113-2235

PPD Clinical Research Unit -Las Vegas /ID# 222363, Las Vegas

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY